Atrial Fibrillation Surgery Market Report

To learn more about this report, Download Free Sample Report

Global Atrial Fibrillation Surgery Market Size

The global atrial fibrillation surgery market size was valued at USD 2.91 billion in 2025 and the global market is forecasted to grow at a CAGR of 14.14% from 2026 to 2034 and reach USD 9.56 billion by 2034 from USD 3.32 billion in 2026.

Atrial Fibrillation (AFib) surgery, most commonly referred to as cardiac ablation or surgical ablation, is a medical procedure used to correct a chaotic and irregular heart rhythm by creating tiny scars in the heart tissue to block faulty electrical signals. These interventions include catheter ablation, surgical maze procedures, and hybrid approaches that isolate pulmonary veins to prevent erratic electrical signals. The market serves a critical role in reducing stroke risk and improving quality of life for millions of affected individuals globally. According to the American Heart Association, atrial fibrillation affects more than 10 million people in the U.S. As per the European Society of Cardiology, the number of individuals with atrial fibrillation is projected to double by 2060. These findings highlight the growing burden on healthcare systems and the necessity for innovative treatment modalities. The definition extends to include minimally invasive techniques that reduce recovery time and hospital stays while maintaining high efficacy rates. Regulatory bodies ensure strict safety standards for devices and procedures used in these complex interventions. This market is integral to modern cardiology supporting both elective and emergency rhythm management strategies across diverse healthcare settings.

MARKET DRIVERS

Rising Prevalence of Atrial Fibrillation Due to Aging Population

The rising prevalence of atrial fibrillation due to an aging population significantly contributes to the growth of the atrial fibrillation surgery market. This demographic shift creates a sustained demand for effective rhythm control interventions. Older adults are disproportionately affected by this condition as age related changes in cardiac tissue increase susceptibility to irregular heartbeats. According to the American Heart Association, the number of individuals with atrial fibrillation is expected to reach 12.1 million in the United States by 2030. This demographic shift ensures a steady influx of patients seeking surgical options when pharmacological treatments fail to manage symptoms adequately. As per the World Health Organization the global population aged 60 years and older will nearly double from 1 billion in 2020 to 2.1 billion by 2050 indicating a massive expansion of the at risk cohort. Healthcare providers prioritize early intervention to prevent complications such as stroke and heart failure which are closely linked to untreated arrhythmias. The availability of minimally invasive surgical techniques encourages earlier adoption among elderly patients who may not tolerate open heart surgery. These factors collectively drive market expansion as hospitals invest in specialized electrophysiology labs and trained personnel to meet the growing clinical demand.

Advancements in Minimally Invasive Surgical Technologies

Advancements in minimally invasive surgical technologies substantially accelerate the expansion of the atrial fibrillation surgery market. These innovations drive growth by improving procedural outcomes and reducing patient recovery times. Modern catheter-based ablation techniques and robotic assisted surgical systems allow physicians to perform complex procedures with greater precision and less trauma than traditional open surgery. According to research, hundreds of thousands of catheter ablation procedures are performed annually in the United States, reflecting widespread acceptance of these options among clinicians and patients. The development of contact force sensing catheters and cryoablation technologies has enhanced success rates and safety profiles making surgery a more attractive option for first line therapy in certain cases. As per studies, minimally invasive surgical approaches for the Cox-Maze IV procedure demonstrate a reduced length of hospital stay compared to conventional sternotomy approaches. Patients benefit from smaller incisions reduced pain and faster return to daily activities which improves overall satisfaction and compliance. Insurance coverage for these advanced techniques has expanded in recent years facilitating greater access for eligible populations. Continuous innovation in energy sources and mapping systems further enhances procedural efficiency. These technological improvements sustain market growth by addressing previous limitations and expanding the candidate pool for surgical intervention.

MARKET RESTRAINTS

High Procedural Costs and Reimbursement Limitations

High procedural costs and reimbursement limitations greatly constrain the growth of the atrial fibrillation surgery market. These factors create significant financial barriers for both healthcare providers and patients. Advanced surgical interventions require expensive equipment specialized training and extended operating room time which drives up the total cost of care. Many insurers impose strict prior authorization requirements or limit coverage to specific indications delaying access to necessary treatments for some patients. According to sources, high out-of-pocket costs and affordability concerns cause a substantial percentage of adults to delay or skip recommended medical treatment. Hospitals in rural or underserved areas often lack the financial resources to invest in state of the art electrophysiology labs limiting geographic access to these services. Variability in reimbursement rates across different regions and payers creates uncertainty for providers planning capacity expansions. This economic constraint slows market penetration and limits the availability of advanced surgical options to wealthier demographics or those with comprehensive insurance plans. Consequently potential growth is curtailed by systemic financial inefficiencies within the healthcare payment structure.

Shortage of Trained Electrophysiologists and Surgical Specialists

A shortage of trained electrophysiologists and surgical specialists considerably obstructs the expansion of the atrial fibrillation surgery market. This deficit creates major barriers in service delivery and increases wait times for patients. Performing complex ablation and maze procedures requires highly specialized skills that take years to develop through rigorous fellowship training programs. According to studies, there is a projected shortage of physicians, including cardiologists and related subspecialists, by 2030. This scarcity limits the number of procedures that can be performed daily and increases the workload on existing specialists leading to potential burnout. As per the Association of American Medical Colleges, fellowship application systems track the progression of general cardiology fellows into specialized clinical cardiac electrophysiology training programs. Rural and community hospitals often struggle to recruit these specialists forcing patients to travel long distances to academic medical centers for care. The steep learning curve associated with new robotic and mapping technologies further delays proficiency among practicing physicians. High turnover rates in healthcare complicate retention of experienced teams. These human resource challenges impede market expansion as institutions cannot scale their surgical capabilities without adequate staffing levels.

MARKET OPPORTUNITIES

Integration of Artificial Intelligence in Procedure Planning

The integration of artificial intelligence in procedure planning unlocks potential for the atrial fibrillation surgery market. This technological application drives progress by enhancing precision and predicting patient-specific outcomes. AI algorithms can analyze extensive cardiac imaging data to identify optimal ablation targets and predict recurrence risks allowing for personalized surgical strategies. According to sources, machine learning algorithms are being trained to optimize ablation parameters and electroanatomical mapping to assist electrophysiologists during procedures. This technological convergence enables surgeons to make data driven decisions that reduce trial and error during complex interventions. As per reports, artificial intelligence applications in the cardiac catheterization lab are being evaluated to optimize workflow efficiency and analysis times. Manufacturers are developing software platforms that integrate seamlessly with existing mapping systems offering real time guidance and feedback during surgery. Hospitals can leverage these tools to standardize care protocols and improve consistency across different operators. Regulatory pathways for AI enabled medical devices are becoming clearer facilitating faster adoption of innovative solutions. This evolution toward intelligent surgery opens new revenue streams through software licensing and service contracts while enhancing clinical value for patients.

Expansion into Hybrid Operating Rooms and Multidisciplinary Care

The expansion into hybrid operating rooms and multidisciplinary care offers a compelling opportunity in the atrial fibrillation surgery market. This infrastructural shift drives growth by facilitating combined surgical and catheter-based approaches. Hybrid procedures allow electrophysiologists and cardiac surgeons to collaborate in real time leveraging the strengths of both minimally invasive and open techniques for complex cases. According to the Society of Thoracic Surgeons hybrid ablation procedures show superior long term freedom from atrial fibrillation compared to standalone catheter ablation in patients with persistent forms of the disease. This collaborative model appeals to patients with advanced disease who have failed previous single modality treatments. As per the American College of Cardiology guidelines increasingly recommend multidisciplinary heart team evaluations for complex arrhythmia cases driving institutional investment in shared infrastructure. Hospitals that establish dedicated hybrid suites can attract referrals for difficult cases and differentiate themselves in competitive markets. Training programs that foster collaboration between specialties enhance team proficiency and patient safety. Payers are beginning to recognize the clinical benefits of hybrid approaches potentially leading to broader coverage policies. This strategic expansion diversifies treatment options and addresses unmet needs in the refractory patient population.

MARKET CHALLENGES

Risk of Procedural Complications and Recurrence

The risk of procedural complications and recurrence is a major obstacle to the atrial fibrillation surgery market. These adverse events can significantly deter both patients and providers from choosing surgical interventions. Despite technological advances complications such as cardiac perforation stroke esophageal injury and phrenic nerve damage remain inherent risks of ablation and maze procedures. According to reports, serious adverse events occur in approximately 2 to 4 % of catheter ablation cases, raising concerns about patient safety. Recurrence of atrial fibrillation after surgery is also common particularly in patients with long standing persistent forms of the condition requiring repeat procedures. As per the Journal of Cardiovascular Electrophysiology up to 30% of patients may experience arrhythmia recurrence within one year of initial ablation necessitating additional medical or surgical management. These outcomes can lead to legal liabilities increased healthcare costs and diminished patient confidence in surgical solutions. Physicians must carefully balance potential benefits against risks when recommending surgery which may limit candidacy for high risk individuals. Improving long term durability of lesions remains a technical hurdle for device manufacturers. Addressing these safety concerns requires continuous innovation and rigorous training to minimize errors and improve patient selection criteria.

Complexity of Patient Selection and Diagnostic Variability

The complexity of patient selection and diagnostic variability is also a significant challenge in the atrial fibrillation surgery market. These inconsistent criteria lead to uneven treatment outcomes and resource utilization. Determining the ideal candidate for surgery versus medical therapy involves assessing multiple factors including symptom burden comorbidities and atrial size which can vary widely among providers. According to the Heart Rhythm Society there is considerable variation in referral patterns for ablation across different regions suggesting a lack of standardized decision making protocols. Some patients may undergo unnecessary procedures while others who would benefit most are delayed due to conservative management approaches. As per the European Society of Cardiology disparities in diagnostic monitoring tools such as wearable devices and implantable loop recorders contribute to inconsistent detection of arrhythmia burden affecting timing of intervention. This variability complicates clinical trial design and real world evidence generation making it difficult to establish universal best practices. Insurance payers often struggle to define clear medical necessity criteria leading to coverage denials and appeals. Standardizing diagnostic workflows and referral guidelines is essential but challenging due to differing local practices and resource availability. These inconsistencies hinder efficient market growth and optimal patient care delivery.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Surgical Procedure Insights

The catheter ablation procedure segment was the most prominent in 2025 and occupied a commanding share of the atrial fibrillation surgery market. Its minimally invasive nature and high efficacy in treating paroxysmal atrial fibrillation supported the prominence of this segment. This approach involves threading a thin tube through blood vessels to the heart to destroy abnormal tissue causing irregular rhythms without open surgery. As per sources, catheter ablation is an established interventional therapy that provides significant rhythm control benefits for selected symptomatic patients. The dominance is driven by shorter hospital stays reduced recovery times and lower complication rates compared to surgical alternatives. As per the Journal of the American College of Cardiology clinical trials demonstrate that catheter ablation provides superior symptom relief and quality of life improvements compared to antiarrhythmic drug therapy alone. Advancements in mapping technologies and energy sources such as radiofrequency and cryoablation have further enhanced success rates and safety profiles. Insurance coverage for these procedures has expanded significantly facilitating broader patient access across diverse demographics. Electrophysiologists prefer this method for its precision and ability to target specific pulmonary vein triggers effectively. The widespread availability of specialized training programs ensures a steady supply of skilled practitioners capable of performing these complex interventions. These factors collectively sustain the segments leadership as it remains the cornerstone of modern arrhythmia management strategies globally.

The maze procedure segment is estimated to register the fastest CAGR of 9% from 2026 to 2034 due to increasing adoption in concurrent cardiac surgeries. This surgical technique creates a pattern of scar tissue in the upper chambers of the heart to block erratic electrical signals often performed during valve replacement or coronary artery bypass grafting. According to reports, the implementation rate of concomitant maze procedures during primary cardiac operations remains underutilized despite clinical guidelines demonstrating a clear survival benefit. The rapid expansion is fueled by strong clinical evidence showing that restoring sinus rhythm reduces stroke risk and improves long term survival outcomes for patients undergoing other heart surgeries. As per the European Journal of Cardio Thoracic Surgery studies indicate that patients who receive maze procedures during mitral valve surgery have significantly better functional capacity and lower recurrence rates compared to those treated with medication alone. Minimally invasive surgical techniques have made the maze procedure more accessible and less traumatic encouraging wider application. Guidelines increasingly recommend routine assessment and treatment of atrial fibrillation during cardiac surgery driving institutional protocol changes. This integration into standard cardiac care pathways propels the segment toward rapid adoption as multidisciplinary teams prioritize comprehensive rhythm management.

By Product Insights

In 2025, the catheter ablation systems segment held the largest share in the atrial fibrillation surgery market because of the high volume of minimally invasive procedures performed globally using these specialized devices. These systems include radiofrequency and cryoablation catheters mapping arrays and generators that enable precise destruction of arrhythmogenic tissue within the heart. According to the American Heart Association catheter ablation is recommended as a class I indication for symptomatic paroxysmal atrial fibrillation ensuring consistent demand for advanced ablation platforms in major medical centers. The dominance is supported by continuous technological innovations such as contact force sensing and pressure monitoring that improve procedural safety and efficacy. As per research, advanced three-dimensional electroanatomical mapping systems are widely integrated with ablation catheters in modern electrophysiology laboratories to manage complex cases. Manufacturers invest heavily in developing next generation catheters with improved flexibility and durability to address challenging anatomies. Reimbursement policies favor these high tech devices when used in accredited centers facilitating their adoption. The recurring revenue model from disposable catheters and accessories ensures stable financial performance for device manufacturers. Established brand loyalty among electrophysiologists further solidifies the segments position as the primary product category driving market revenue and innovation.

The surgical ablation devices segment is anticipated to witness the fastest CAGR of 10% during the forecast period, owing to the rise of standalone minimally invasive surgical approaches. These devices include bipolar clamps pen based ablation tools and epicardial probes designed for use in thoracoscopic or hybrid procedures outside the traditional operating room setting. According to studies, standalone minimally invasive surgical ablation is considered a viable alternative for patients who have failed catheter ablation or have persistent atrial fibrillation. The rapid expansion is fueled by the development of specialized instruments that allow for precise lesion creation on the beating heart without cardiopulmonary bypass. As per the Journal of Thoracic and Cardiovascular Surgery clinical outcomes demonstrate that surgical ablation devices offer higher long term freedom from atrial fibrillation compared to repeat catheter procedures in difficult cases. Hospitals are investing in hybrid operating rooms equipped with these advanced surgical tools to support multidisciplinary care models. Training initiatives for cardiac surgeons in minimally invasive techniques are expanding the pool of qualified providers. The ability to address non pulmonary vein triggers surgically provides a unique value proposition. These factors drive robust demand for innovative surgical ablation technologies as treatment algorithms evolve to include earlier surgical intervention.

REGIONAL ANALYSIS

North America Atrial Fibrillation Surgery Market Analysis

North America led the atrial fibrillation surgery market and captured a significant share in 2025. The region stands as the most advanced regional market, characterized by high adoption rates of innovative technologies. In addition, the region dominates global demand due to its robust healthcare infrastructure favorable reimbursement policies and high prevalence of atrial fibrillation among an aging population. According to the Centers for Disease Control and Prevention atrial fibrillation affects approximately 6 million people in the United States creating a substantial patient base for surgical interventions. The presence of leading medical device manufacturers and world class research institutions fosters continuous innovation and rapid commercialization of new ablation technologies. As per sources, North America represents a substantial share of global catheter ablation procedures, reflecting deep clinical integration and physician familiarity with advanced techniques. High healthcare expenditure per capita enables access to premium devices and specialized care centers. Regulatory pathways through the Food and Drug Administration are well established facilitating timely market entry for breakthrough products. Strong professional societies provide extensive training and guidelines ensuring high standards of care. These factors ensure North America remains the primary engine of growth and technological leadership in the global atrial fibrillation surgery landscape.

Europe Atrial Fibrillation Surgery Market Analysis

Europe was positioned second in the atrial fibrillation surgery market in 2025. This growth was fuelled by universal healthcare coverage and stringent regulatory standards that prioritize patient safety and clinical efficacy. The region exhibits steady growth driven by an aging demographic and increasing awareness of stroke prevention strategies linked to arrhythmia management. According to the European Society of Cardiology atrial fibrillation is the most common sustained cardiac arrhythmia in Europe affecting over 11 million individuals which sustains consistent demand for surgical solutions. Countries like Germany France and the United Kingdom lead in adopting hybrid operating rooms and advanced mapping systems for complex cases. As per the Eurostat, healthcare spending in the European Union averages 10 % of gross domestic product, supporting investment in specialized electrophysiology centers and trained personnel. Reimbursement frameworks vary by country but generally cover guideline recommended ablation procedures ensuring broad patient access. Collaborative research networks across borders facilitate knowledge sharing and standardization of best practices. The Medical Device Regulation implementation has raised quality benchmarks encouraging manufacturers to invest in robust clinical evidence. These elements ensure Europe remains a key market with stable growth and high clinical standards for atrial fibrillation interventions.

Asia Pacific Atrial Fibrillation Surgery Market Analysis

The Asia Pacific region maintains a rapidly emerging position in the atrial fibrillation surgery market due to improving healthcare infrastructure, rising disposable incomes, and increasing disease awareness. Countries such as China Japan and India are witnessing a surge in diagnostic rates and subsequent referrals for surgical management of atrial fibrillation. According to reports, the number of people aged 60 and older in the Asia-Pacific region is expected to triple between 2010 and 2050, creating a massive future demand for age-related cardiac care. Government initiatives to expand insurance coverage and build specialized heart centers are accelerating market penetration in previously underserved areas. As per research, the absolute burden of atrial fibrillation in the Asia-Pacific region is increasing rapidly due to aging populations and an rising prevalence of cardiovascular risk factors. Local manufacturing capabilities are growing reducing costs and increasing accessibility of ablation devices. Medical tourism hubs in Thailand and Singapore attract international patients seeking high quality affordable surgical care. Training programs for electrophysiologists are expanding rapidly to meet the growing clinical workload. These dynamics position Asia Pacific as the highest growth region with significant potential for volume expansion in the coming decade.

Latin America Atrial Fibrillation Surgery Market Analysis

Latin America is expanding gradually in the atrial fibrillation surgery market. The region has economic disparities and varying levels of healthcare development. Major economies like Brazil and Mexico lead the region in adopting advanced ablation technologies primarily in private hospitals and urban academic centers. According to the Pan American Health Organization cardiovascular diseases are the leading cause of death in Latin America driving government focus on improving cardiac care infrastructure and access to specialized treatments. Public healthcare systems face budget constraints limiting widespread adoption of expensive surgical devices but private insurance sectors show robust demand. As per studies, investments in digital health innovation and healthcare infrastructure across major Latin American cities support the acquisition of modern medical technologies. Medical professionals increasingly participate in international training programs bringing back expertise in minimally invasive techniques. Distribution networks for global device manufacturers are expanding to reach remote areas though challenges remain. Economic volatility can impact purchasing power but long term demographic trends support market growth. These factors ensure Latin America remains a developing market with untapped potential for expanded surgical interventions.

Middle East and Africa Atrial Fibrillation Surgery Market Analysis

The Middle East and Africa region is likely to grow notably in the Atrial Fibrillation Surgery Market during the forecast period, owing to significant investment in healthcare modernization, particularly in Gulf Cooperation Council countries. Nations like Saudi Arabia and the United Arab Emirates are building world class medical cities and attracting top international talent to perform complex cardiac procedures. According to the World Bank healthcare expenditure in the Middle East has grown by 6% annually reflecting strong government commitment to improving public health outcomes and reducing reliance on medical tourism abroad. The prevalence of risk factors such as diabetes and hypertension contributes to rising atrial fibrillation cases necessitating advanced surgical management. As per reports, efforts to strengthen health systems in Africa include training local specialists in cardiovascular medicine, though access to subspecialties like electrophysiology remains limited in rural areas. Private sector growth in major urban centers drives demand for premium ablation devices and hybrid operating rooms. International partnerships facilitate technology transfer and capacity building for local healthcare providers. While market size is smaller compared to other regions the rate of infrastructure development is rapid. These elements position the Middle East and Africa as a niche but growing market with increasing sophistication in cardiac care delivery.

COMPETITIVE LANDSCAPE

The competitive landscape of the Atrial Fibrillation Surgery Market is characterized by intense rivalry among established medical device giants and emerging innovators focusing on specialized ablation technologies. Key participants compete primarily on clinical efficacy ease of use and integration with digital health platforms rather than price alone. The market features a mix of dominant players in catheter based systems and growing competitors in surgical ablation devices for hybrid procedures. Companies strive to differentiate themselves through proprietary mapping algorithms energy delivery mechanisms and robotic assistance features that enhance procedural safety. Regulatory compliance with stringent health authority standards serves as a significant barrier to entry favoring organizations with robust quality management systems. Strategic partnerships with hospitals and research institutions drive clinical validation and adoption while fostering innovation through collaborative studies. The absence of monopolistic control encourages continuous technological advancement and diversification of product portfolios. Participants increasingly focus on building comprehensive ecosystems that include training services data analytics and remote patient monitoring to enhance customer retention. This dynamic environment rewards companies that can demonstrate tangible improvements in long term success rates and patient quality of life.

KEY MARKET PLAYERS

Some of the notable players operating the global atrial fibrillation surgery market include

• Thermo Fisher Scientific, Inc.
• G.E. Healthcare
• QIAGEN N.V.
• Life Technologies
• Agilent Technologies
• Roche
• PerkinElmer
• Affymetrix
• Illumina, Inc.
• Bio-Rad Laboratories
• Oxford Gene Technology
• Luminex Corporation

Top Players Contribution

Johnson and Johnson

Johnson and Johnson maintains a dominant presence in the Atrial Fibrillation Surgery Market through its Biosense Webster division which specializes in advanced catheter ablation technologies. The company focuses on integrating artificial intelligence into mapping systems to enhance procedural precision and reduce operation time for electrophysiologists. Recent initiatives include the launch of next generation contact force sensing catheters that provide real time feedback during complex arrhythmia treatments. This strategic innovation ensures superior clinical outcomes and strengthens trust among healthcare providers globally. Johnson and Johnson actively collaborates with leading academic institutions to conduct clinical trials validating the efficacy of their latest ablation platforms. Their commitment to education involves extensive training programs for physicians ensuring optimal utilization of sophisticated equipment. By prioritizing technological leadership they solidify their reputation as a premier provider of comprehensive rhythm management solutions. These efforts enable the company to sustain its competitive edge despite increasing market rivalry.

Medtronic

Medtronic contributes significantly to the market through its diverse portfolio of cryoablation and radiofrequency ablation systems designed for treating atrial fibrillation effectively. The company emphasizes minimally invasive approaches that offer faster recovery times and reduced hospital stays for patients undergoing cardiac procedures. They recently expanded their Arctic Front Advance platform capabilities to address persistent forms of the condition with improved lesion durability. Medtronic invests heavily in digital health integration allowing remote monitoring of patient data post procedure to prevent recurrence. The firm partners with hospitals worldwide to establish centers of excellence that promote best practices in electrophysiology. Their focus on user friendly device design simplifies the learning curve for new practitioners entering the field. These actions enhance accessibility and drive widespread adoption of their technologies across diverse healthcare settings.

Abbott Laboratories

Abbott Laboratories strengthens its position by offering innovative mapping and navigation systems that complement their ablation catheter offerings for precise cardiac interventions. The company leverages its EnSite platform to create detailed three dimensional models of patient hearts enabling tailored treatment strategies for complex cases. They recently introduced high density mapping catheters that capture more electrical data points improving the accuracy of arrhythmia source identification. Abbott focuses on streamlining workflow efficiency in electrophysiology labs through automated data analysis tools that reduce manual interpretation errors. The firm also provides robust technical support and service networks ensuring minimal downtime for critical medical equipment. Their commitment to continuous improvement drives regular software updates that enhance system performance without hardware replacements. These strategies enable Abbott to capture significant market share by delivering value through precision and operational efficiency.

Top Strategies Used by Key Market Participants

Strategies employed by key market participants include aggressive investment in research and development to pioneer next generation ablation technologies with higher precision and safety profiles. Companies actively pursue mergers and acquisitions to acquire niche technologies or expand their geographic reach in emerging markets. Product diversification remains a core strategy with firms developing modular systems that can be adapted for various arrhythmia types to maximize return on investment. Investment in artificial intelligence and machine learning enables predictive modeling and real time guidance creating value added services beyond hardware sales. Collaborations with insurance providers facilitate broader reimbursement coverage for advanced procedures enhancing patient access and institutional adoption. Emphasis on physician training and certification programs builds brand loyalty and ensures proper utilization of complex systems. Customer centric approaches such as flexible financing options and comprehensive service contracts lower initial barriers for smaller healthcare facilities. These multifaceted strategies enable companies to build resilient market positions and capture growth opportunities across diverse clinical settings.

RECENT MARKET HAPPENINGS

• In October 2022, the first radiofrequency balloon ablation catheter by the name HELIOSTAR was launched in Europe by a med tech company which is a part of Johnson and Johnson called biosense Webster. The machine is designed to help make cardiac ablations more efficient and to help make the job easier for physicians.  
• In October 2022, an attempt is being made to create an ablation technology that does not cause any side effects like damage to areas other than the targetted in the heart by a technological company called Stem Tronics. In addition, a significant investigation device exemption trial is being performed to produce pulsed electric fields and target specific heart regions. 
• In October 2022, Heartbeam, a heart device manufacturing company, initiated the development of a heart device that can be connected to the patient's smartwatch for continuous monitoring of the heart in various patterns, including atrial fibrillation. The California-based company is creating this wearable device to make it easier for remote health monitoring systems. 
• In May 2020, the US FDA approved the next-generation CardioFocus Inc. HeartLight X3 Endoscopic ablation system to treat drug-refractory recurrent symptomatic paroxysmal atrial fibrillation. 

MARKET SEGMENTATION

This research report on the global atrial fibrillation surgery market has been segmented and sub-segmented based on the surgical procedure, product, and region.

By Surgical Procedure

• Catheter Ablation procedure
• Surgical Ablation
• Maze procedure

By Product

• Catheter Ablation Devices
• Surgical Ablation Devices

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa